[go: up one dir, main page]

CO2018003969A2 - Compuestos de imidazo[4,5-c]quinolin-2-ona - Google Patents

Compuestos de imidazo[4,5-c]quinolin-2-ona

Info

Publication number
CO2018003969A2
CO2018003969A2 CONC2018/0003969A CO2018003969A CO2018003969A2 CO 2018003969 A2 CO2018003969 A2 CO 2018003969A2 CO 2018003969 A CO2018003969 A CO 2018003969A CO 2018003969 A2 CO2018003969 A2 CO 2018003969A2
Authority
CO
Colombia
Prior art keywords
compounds
salts
quinolin
imidazo
pharmaceutically acceptable
Prior art date
Application number
CONC2018/0003969A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Thomas Anthony Hunt
Andrew John Eatherton
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2018003969A2 publication Critical patent/CO2018003969A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPUESTOS DE IMIDAZO[4,5-C]QUINOLIN-2-ONA Y SU USO EN EL TRATAMIENTO DEL CÁNCER" La memoria descriptiva se refiere en general a compuestos de Fórmula (I): (I) y sales farmacéuticamente aceptables de los mismos, donde x, R1, R2, R3, R4 y R5 tienen cualquiera de los significados definidos en el presente documento. La memoria descriptiva también se refiere al uso de compuestos de Fórmula (I) y sales de estos para tratar o prevenir una enfermedad mediada por ATM, incluido el cáncer. Esta memoria descriptiva se refiere además a composiciones farmacéuticas que comprenden compuestos de tipo imidazo[4,5-c]quinolin-2-ona sustituidos y sales farmacéuticamente aceptables de estos; kits que comprenden tales compuestos y sales; métodos de producción de tales compuestos y sales; e intermedios útiles en tal producción.
CONC2018/0003969A 2015-11-03 2018-04-13 Compuestos de imidazo[4,5-c]quinolin-2-ona CO2018003969A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1519406.1A GB201519406D0 (en) 2015-11-03 2015-11-03 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PCT/EP2016/076412 WO2017076895A1 (en) 2015-11-03 2016-11-02 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CO2018003969A2 true CO2018003969A2 (es) 2018-07-10

Family

ID=55130605

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0003969A CO2018003969A2 (es) 2015-11-03 2018-04-13 Compuestos de imidazo[4,5-c]quinolin-2-ona

Country Status (20)

Country Link
US (1) US20180318287A1 (es)
EP (1) EP3371183A1 (es)
JP (1) JP2018536649A (es)
KR (1) KR20180070703A (es)
CN (1) CN108349971A (es)
AU (1) AU2016348546B2 (es)
BR (1) BR112018007772A2 (es)
CA (1) CA3002608A1 (es)
CL (1) CL2018001146A1 (es)
CO (1) CO2018003969A2 (es)
CR (1) CR20180307A (es)
GB (1) GB201519406D0 (es)
HK (2) HK1255598A1 (es)
IL (1) IL258818A (es)
MX (1) MX2018005445A (es)
PE (1) PE20181345A1 (es)
PH (1) PH12018500958A1 (es)
RU (1) RU2018120318A (es)
SV (1) SV2018005663A (es)
WO (1) WO2017076895A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
US12226414B2 (en) 2018-09-14 2025-02-18 Suzhou Zanrong Pharma Limited 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (ATM) kinase and uses thereof
AU2019348132B2 (en) * 2018-09-30 2022-03-31 Medshine Discovery Inc. Quinolino-pyrrolidin-2-one derivative and application thereof
CA3131156A1 (en) * 2019-03-05 2020-09-10 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
CN115003672A (zh) * 2020-01-09 2022-09-02 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
CN115380031A (zh) * 2020-03-30 2022-11-22 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
TW202216209A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atm抑制劑之組合
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes
AU2021433713A1 (en) 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN118434736A (zh) * 2022-01-26 2024-08-02 正大天晴药业集团股份有限公司 含有肼基的化合物
CA3245563A1 (en) * 2022-04-11 2023-10-19 Wei Zhong CRYSTALLINE FORM OF DERIVED 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO [4,5-C]QUINOLIN-2-ONE, CRYSTALLINE SALT FORM, PREPARATION AND APPLICATION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2438063A1 (en) * 2009-06-04 2012-04-11 Novartis AG 1h-imidazo[4,5-c]quinolinone compounds, useful for the treatment of proliferative diseases
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (es) * 2014-05-08 2018-04-21
CN111689963A (zh) * 2015-04-02 2020-09-22 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途

Also Published As

Publication number Publication date
CN108349971A (zh) 2018-07-31
SV2018005663A (es) 2018-07-20
RU2018120318A3 (es) 2019-12-24
MX2018005445A (es) 2018-08-14
AU2016348546A1 (en) 2018-06-14
BR112018007772A2 (pt) 2018-10-30
EP3371183A1 (en) 2018-09-12
HK1257678A1 (zh) 2019-10-25
GB201519406D0 (en) 2015-12-16
RU2018120318A (ru) 2019-12-05
CA3002608A1 (en) 2017-05-11
US20180318287A1 (en) 2018-11-08
IL258818A (en) 2018-06-28
KR20180070703A (ko) 2018-06-26
CR20180307A (es) 2018-10-05
PH12018500958A1 (en) 2018-11-19
JP2018536649A (ja) 2018-12-13
PE20181345A1 (es) 2018-08-22
WO2017076895A1 (en) 2017-05-11
HK1255598A1 (zh) 2019-08-23
AU2016348546B2 (en) 2019-05-02
CL2018001146A1 (es) 2018-09-04

Similar Documents

Publication Publication Date Title
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
ECSP19066134A (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CR20170546A (es) Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios